<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10475">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02970591</url>
  </required_header>
  <id_info>
    <org_study_id>Car-IBS 1511-01</org_study_id>
    <nct_id>NCT02970591</nct_id>
  </id_info>
  <brief_title>A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome</brief_title>
  <acronym>Car-IBS</acronym>
  <official_title>A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome; Traditional Dietary Advice Including Low FODMAP Content, vs a Low Carbohydrate Diet vs Optimized Medical Treatment for Adult Patients With IBS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Funding: Kostfonden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Funding: Skandia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Funding: Nanna Svartz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <brief_summary>
    <textblock>
      Irritable Bowel Syndrome is a common disease to which there is no curable treatment. Diet is
      considered to trigger symptoms associated with the clinical picture of IBS, and dietary
      treatment is thus believed to relieve the symptoms of IBS. As the disease is very
      heterogeneous in its manifestation, different treatment options might be indicated depending
      on the predominant symptom. To investigate the response to different dietary treatment
      options, a randomized controlled intervention trial will be carried out in adult patients
      (&gt;18 y) with IBS according to Rome III criteria. The aim of this study is to compare the
      response to two different dietary treatments or optimized medical treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in IBS-SSS</measure>
    <time_frame>Baseline, 4 weeks, 3 and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic profile</measure>
    <time_frame>Baseline, 4 weeks, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota content</measure>
    <time_frame>Baseline, 4 weeks, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Diet A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low FODMAP diet including traditional dietary advice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low carbohydrate diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Optimized Medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Traditional dietary advice and low FODMAP content</intervention_name>
    <description>Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.</description>
    <arm_group_label>Diet A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low carbohydrate diet</intervention_name>
    <description>Diet that contains a maximum of 10 energy percent of carbohydrates, 25 energy % proteins and 65 energy % fat.</description>
    <arm_group_label>Diet B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimized Medical treatment</intervention_name>
    <description>Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.</description>
    <arm_group_label>Medical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IBS according to ROME III criteria, BMI 18-35, ability to communicate on Swedish

        Exclusion Criteria:

          -  Heart, liver, neurologic or psychiatric disease or illness

          -  Serious gastrointestinal diseases

          -  Celiac disease

          -  Diabetes

          -  Other conditions or surgery that affects the gastrointestinal function

          -  Hyperlipidemia

          -  Food allergy or intolerance other than lactose

          -  Adherence to a specific diet

          -  Being pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dept of Internal Medicine, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 19, 2017</lastchanged_date>
  <firstreceived_date>November 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Magnus Simr√©n</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>FODMAPS</keyword>
  <keyword>carbohydrates</keyword>
  <keyword>metabolomics</keyword>
  <keyword>microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
